Syndax Pharmaceuticals, a late-stage biotech developing a novel therapy for treatment-resistant breast cancer, refiled on Monday with the SEC to raise up to $86 million in an initial public offering.
The company originally set terms in June 2014 to raise $60 million, but withdrew its offering.
The Waltham, MA-based company was founded in 2005 and plans to list on the Nasdaq under the symbol SNDX. Syndax Pharmaceuticals filed confidentially on August 25, 2015. Morgan Stanley and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
